SCHEMBL17469492

SCHEMBL17469492

CNCCN(C)Cc1n[nH]c2ccc(OCc3ccc(C(N)=O)cc3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 5/20 0.43
▸ TTK P33981 2/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ FLT3 P36888 3/20 0.41
▸ MAOB P27338 2/20 0.39
▸ ALOX5 P09917 1/20 0.38
▸ FGFR4 P22455 1/20 0.38
▸ KIT P10721 2/20 0.38
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ MAP2K4 P45985 1/20 0.36
▸ MAPKAPK2 P49137 1/20 0.36
▸ MAPKAPK3 Q16644 1/20 0.36
▸ MAPK6 Q16659 1/20 0.36
▸ MAPKAPK5 Q8IW41 1/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17469501 0.92 FLT3 (0.41) TTKMAPK8FLT3MAOBALOX5
SCHEMBL17469514 0.90 TTK (0.48) PARP10TTKMAPK8FLT3MAOB
SCHEMBL19245440 0.86 TTK (0.50) TTKMAPK8FLT3FGFR4LMNA
SCHEMBL17469475 0.86 HTR1D (0.46) TTKFLT3MAOBFGFR4CARM1
SCHEMBL16129387 0.85 FGFR4 (0.45) TTKFLT3MAOBFGFR4CARM1
SCHEMBL20066384 0.84 PRMT1 (0.43) MAOBFGFR4CARM1PRMT1
SCHEMBL17469493 0.84 APP (0.38) TTKFLT3MAOBFGFR4CARM1
SCHEMBL17469495 0.84 MAOB (0.42) TTKMAPK8FLT3MAOBCARM1
SCHEMBL17469454 0.83 MAOB (0.41) MAOBKITCARM1PRMT1
SCHEMBL16129388 0.83 MAOB (0.43) MAOBCARM1PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2018-04-19 — — US disclosed
US-9765035-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2017-09-19 — — US disclosed
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024017-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PARP10 307/4885TTK 3253/4885MAPK8 2396/4885
US-20180105497-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PARP10 307/4885TTK 3253/4885MAPK8 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback